zanubrutinib
E890926
Bruton tyrosine kinase inhibitor
anticancer drug
orally administered drug
protein kinase inhibitor
small-molecule drug
Zanubrutinib is a small-molecule Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
All labels observed (1)
| Label | Occurrences |
|---|---|
| zanubrutinib canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T10837769 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: zanubrutinib Context triple: [Bruton tyrosine kinase, isTherapeuticTargetOf, zanubrutinib]
-
A.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
B.
acalabrutinib
Acalabrutinib is a second-generation, highly selective Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
C.
Venclexta
Venclexta is a targeted cancer therapy (venetoclax) used primarily to treat certain types of leukemia by inhibiting the BCL-2 protein that helps cancer cells survive.
-
D.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
E.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: zanubrutinib Target entity description: Zanubrutinib is a small-molecule Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
A.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
B.
acalabrutinib
Acalabrutinib is a second-generation, highly selective Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
C.
Venclexta
Venclexta is a targeted cancer therapy (venetoclax) used primarily to treat certain types of leukemia by inhibiting the BCL-2 protein that helps cancer cells survive.
-
D.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
E.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
- F. None of above. chosen
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
Bruton tyrosine kinase inhibitor
ⓘ
anticancer drug ⓘ orally administered drug ⓘ protein kinase inhibitor ⓘ small-molecule drug ⓘ |
| approvalYearInUS | 2019 ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
Therapeutic Goods Administration ⓘ U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| belongsToClass | second-generation BTK inhibitors ⓘ |
| boxedWarning | none as of 2024 ⓘ |
| commonAdverseEffect |
diarrhea
ⓘ
neutropenia ⓘ rash ⓘ thrombocytopenia ⓘ upper respiratory tract infection ⓘ |
| contraindication | known hypersensitivity to zanubrutinib ⓘ |
| developedBy | BeiGene ⓘ |
| dosageForm |
oral capsule
ⓘ
oral tablet ⓘ |
| drugInteraction |
strong CYP3A inducers
ⓘ
strong CYP3A inhibitors ⓘ |
| eliminationRoute |
feces
ⓘ
urine ⓘ |
| hasATCCode | L01EL02 ⓘ |
| hasCASNumber | 1691240-69-7 ⓘ |
| hasChEMBLID | CHEMBL3403544 ⓘ |
| hasDrugBankID | DB15035 ⓘ |
| hasHalfLife | approximately 2 to 4 hours ⓘ |
| hasIUPACName | (3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-(1H-pyrazol-4-yl)azetidin-3-ol ⓘ |
| hasPubChemCID | 71226668 ⓘ |
| hasTradeName | Brukinsa ⓘ |
| hasUNIID | 9JX8XQ24NU ⓘ |
| indication |
Waldenström macroglobulinemia
ⓘ
chronic lymphocytic leukemia ⓘ mantle cell lymphoma ⓘ marginal zone lymphoma ⓘ relapsed or refractory chronic lymphocytic leukemia ⓘ relapsed or refractory mantle cell lymphoma ⓘ small lymphocytic lymphoma ⓘ
linked to:
chronic lymphocytic leukemia
|
| mechanismOfAction | covalent inhibition of Bruton tyrosine kinase ⓘ |
| metabolizedBy |
CYP3A
ⓘ
linked to:
CYP3A4
|
| pregnancyCategory | may cause fetal harm ⓘ |
| proteinBinding | high ⓘ |
| routeOfAdministration | oral ⓘ |
| selectivity | highly selective for BTK compared with first-generation inhibitors ⓘ |
| seriousAdverseEffect |
atrial fibrillation
ⓘ
hemorrhage ⓘ infections ⓘ |
| targets | Bruton tyrosine kinase ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: zanubrutinib Description of subject: Zanubrutinib is a small-molecule Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.